文献速递物质与行为成瘾

米氮平治疗甲基苯丙胺使用障碍:一项随机临床试验

Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2026-01-01

这项在澳大利亚6个门诊开展的3期双盲安慰剂对照试验,纳入344名中重度甲基苯丙胺使用障碍成人,比较米氮平30mg/日与安慰剂共12周。

要点

  • 米氮平30mg/日治疗12周可小幅减少甲基苯丙胺使用天数,差异有统计学意义。
  • 抑郁、失眠、HIV风险行为、生活质量及尿检阴性率等次要终点均无显著改善。
  • 米氮平组嗜睡(47% vs 33%)、体重增加(10% vs 3%)及不良事件停药(23% vs 15%)更多。

核心结论

  • 在常规临床实践中,米氮平可减少成人甲基苯丙胺使用障碍患者的甲基苯丙胺使用天数。
  • 未发现该场景下米氮平的非预期安全性问题,但不良事件相关停药率高于安慰剂。

研究设计与样本

  • 纳入中重度甲基苯丙胺使用障碍成人,随机分配至米氮平30mg/日或等效安慰剂,疗程12周,共344人随机、339人接受干预。

主要发现

  • 从基线至第12周,米氮平组过去28天甲基苯丙胺使用天数平均减少7.0天,安慰剂组减少4.8天。
  • 次要终点(抑郁、失眠、HIV风险行为、生活质量、甲基苯丙胺阴性口腔液样本)均无显著效应。

关键数值与推荐

  • 主要终点为基线至第12周过去28天甲基苯丙胺使用天数的变化。
  • 米氮平组嗜睡报告率47%、体重增加10%;安慰剂组分别为33%和3%。

临床怎么用

  • 对于中重度甲基苯丙胺使用障碍成人,米氮平可作为减少使用天数的药物选择之一,但获益幅度有限。
  • 用药期间需关注嗜睡和体重增加,并监测因不良事件导致的停药风险。
  • 不应期望米氮平同步改善抑郁、失眠或HIV风险行为等次要结局。

局限性

  • 原文未报告研究局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Methamphetamine use disorder is a global health challenge for which there are no approved pharmacotherapies. The safety and effectiveness of mirtazapine, a promising candidate for methamphetamine use disorder, has not been established in routine clinical practice. OBJECTIVE: To determine the safety and effectiveness of mirtazapine as a pharmacotherapy for methamphetamine use disorder in routine clinical practice. DESIGN, SETTING, AND PARTICIPANTS: This phase 3, parallel-group, double-blind, placebo-controlled randomized clinical trial was conducted between November 16, 2022, and May 1, 2025, at 6 outpatient alcohol and other drug clinics in Australia among adults with moderate to severe methamphetamine use disorder. Data analysis was conducted from May to September 2025. INTERVENTION: Mirtazapine (30 mg daily for 12 weeks) or equivalent placebo. MAIN OUTCOMES AND MEASURES: The primary end point was the change in days of methamphetamine use in the past 28 days from baseline to week 12. Secondary end points were depression, insomnia, HIV risk behavior, quality of life, and methamphetamine-negative oral fluid samples. RESULTS: Of 344 participants randomized, 339 participants received the intervention (167 in the placebo group and 172 in the mirtazapine group). Mean (SD) age was 42.0 (8.6) years, 126 participants (37.2%) were female, and participants had used methamphetamine for a median (IQR) of 24 days (17-28) of the past 28 days at baseline. The mean reduction in days of methamphetamine use from baseline to week 12 was greater in the mirtazapine group (7.0 days of 28 days) than in the placebo group (4.8 days of 28 days; mean difference, 2.2 days; 95% CI, -4.2 to -0.2 days; P = .02). More participants in the mirtazapine group reported drowsiness (47% vs 33%) and weight gain (10% vs 3%). Forty participants (23%) discontinued mirtazapine due to adverse events compared to 25 participants (15%) in the placebo group. No significant effects of mirtazapine on secondary end points were found. CONCLUSIONS AND RELEVANCE: In this parallel-group randomized clinical trial, mirtazapine delivered in routine clinical practice reduced methamphetamine use in adults with methamphetamine use disorder. No unexpected safety concerns delivering mirtazapine in this setting were found; this finding has important clinical implications in the absence of any approved pharmacotherapies for methamphetamine use disorder. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12622000235707.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. McKetin R, Shoptaw S, Saunders L, et al. Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2026. PMID: 41920558. doi:10.1001/jamapsychiatry.2026.0159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。